1. Pink Sheet
  2. >>Archive

Ipsen Confident in U.S. Neurology Push Despite Dysport Delay

 
• By Melanie Senior

Neither FDA’s REMS request nor the prospect of competing with Allergan’s Botox appears to be spoiling Ipsen’s plans to stake a U.S. neurology stronghold.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet